Back to search

Article

Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinoma

2026-01-23

Abstract excerpt

<h4>ABSTRACT</h4> The limited efficacy of current therapies against cholangiocarcinoma (CCA) necessitates the development of novel treatment strategies. Src family kinases (SFKs) contribute significantly to tumor progression and resistance in CCA. Therefore, we investigated the novel, first-in-class SFK ‘OFF’ inhibitor NXP900 in diverse preclinical CCA models, including those with acquired resistance. This study...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
bb98955e-2d41-5d17-8fbe-0bef942ef5bc
DOI
10.64898/2026.01.21.699926
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinomaDOI 10.64898/2026.01.21.699926
LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinomaSemantic proximity
Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology.Semantic proximity
Molecular Subtypes and Precision Oncology in Intrahepatic CholangiocarcinomaSemantic proximity
Molecular mechanisms and genetic features of cholangiocarcinoma: implications for targeted therapeutic strategiesSemantic proximity
Signalling networks in cholangiocarcinoma: Molecular pathogenesis, targeted therapies and drug resistanceSemantic proximity
The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets.Semantic proximity
The evolving role of futibatinib for advanced cholangiocarcinoma.Semantic proximity
Individualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft.Semantic proximity
A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma.Semantic proximity
Integrative multiomics enhancer activity profiling identifies therapeutic vulnerabilities in cholangiocarcinoma of different etiologiesSemantic proximity
Developments in FGFR and IDH inhibitors for cholangiocarcinoma therapy.Semantic proximity
Heterogeneity, Inherent and Acquired Drug Resistance in Patient-Derived Organoids Models of Primary Liver CancerSemantic proximity
Select a neighboring publication to make it the new centre.